In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia

FEMS Microbiology Letters

Volumn 285, Issue 1, 2008, Pages 40-50

  Treerat, Puthayalai ^a   Widmer, Fred ^b   Middleton, Peter G ^b   Iredell, Jon ^b   George, Anthony M ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Amilorides; Burkholderia; Cystic fibrosis; Pseudomonas; Tobramycin

Indexed keywords

AMIKACIN; AMILORIDE; AMLODIPINE; BENZAMIL; CHLORIDE ION; PHENAMIL; POTASSIUM ION; SALBUTAMOL; SODIUM ION; TOBRAMYCIN; VERAPAMIL;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOFILM; BURKHOLDERIA CENOCEPACIA; COLONY FORMING UNIT; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG PENETRATION; DRUG STRUCTURE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SODIUM TRANSPORT;

AMILORIDE; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MEMBRANE TRANSPORT MODULATORS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 47349087792     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/j.1574-6968.2008.01219.x     Document Type: Article

References (37)

1. Aronoff SC Klinger JD (1984) In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis. Antimicrob Agents Chemother 25:279 280.
2. Asok Kumar K, Mazumdar K, Dutta NK, Karak P, Dastidar SG Ray R (2004) Evaluation of synergism between the aminoglycoside antibiotic streptomycin and the cardiovascular agent amlodipine. Biol Pharm Bull 27:1116 1120.
3. Boucher RC (2002) An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev 54:1359 1371.
4. Brand PLP (2000) Bronchodilators in cystic fibrosis. 93:37 39.
5. Campana S, Taccetti G, Ravenni N, Masi I, Audino S, Sisi B, Repetto T, Doring G de Martino M (2004) Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex, and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. J Cyst Fibros 3:159 163.
6. Coenye T, Vandamme P, Govan JRW LiPuma JJ (2001) Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 39:3427 3436.
7. Cohn RC Aronoff SC (1989) The effect of sodium on amiloride-tobramycin synergy in Pseudomonas cepacia. J Lab Clin Med 114:724 727.
8. Cohn RC, Jacobs M Aronoff SC (1988) In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 32:395 396.
9. Cohn RC, Rudzienski L Putnam RW (1992) In vitro antimicrobial activity of amiloride analogs against Pseudomonas. Chemotherapy 38:232 234.
10. Cohn RC, Rudzienski L Putnam RW (1995) Verapamil-tobramycin synergy in Pseudomonas cepacia but not Pseudomonas aeruginosa in vitro. Chemotherapy 41:330 333.
11. Conway SP (2005) Nebulized antibiotic therapy: the evidence. Chron Respir Dis 2:35 41.
12. Dorwart M, Thibodeau P Thomas P. (2004) Cystic fibrosis: recent structural insights. J Cyst Fibros 3:91 94.
13. Drumm M (1999) What happens to ΔF508 in vivo? J Clin Invest 103:1369 1370.
14. Frangolias DD, Mahenthiralingam E, Rae S, Raboud JM, Davidson AG, Wittman R Wilcox PG (1999) Burkholderia cepacia in cystic fibrosis. Am J Respir Crit Care Med 160:1572 1577.
15. Gilligan PH (1991) Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4:35 51.
16. Govan JR Deretic V (1996) Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60:539 574.
17. Hancock REW Speert DP (2000) Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Res Updates 3:247 255.
18. Hoffman LR, D'Argenio DA, MacCross MJ, Zhang Z, Jones RA Miller SI (2005) Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436:1171 1175.
19. Hoiby N, Frederikson B Pressler T (2005) Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2:49 54.
20. Isenberg DH (1998) Broth microdilution MIC test. Essential procedures for clinical microbiology (Isenberg DH, ed.), pp. 216 223. ASM Press, Washington, DC.
21. Kleyman TR Cragoe EJ Jr. (1988) Amiloride and its analogs as tools in the study of ion transport. J Membr Biol 105:1 21.
22. Kwon DH Lu CD (2006) Polyamines increase antibiotic susceptibility in Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:1623 1627.
23. Leviton IM, Fraimow HS, Carrasco N, Dougherty TJ Miller MM (1995) Tobramycin uptake in Escherichia coli membrane vesicles. Antimicrobial Agents Chemother 39:467 475.
24. Lewin C, Doherty C Govan J (1993) In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother 37:123 125.
25. Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Grevelle AM, Wong LT, Davidson AG, Wilcox PG, Nakielna B Speert DP (2001) Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 33:1469 1475.
26. Manno G, Cruciani M, Romano L, Scapolan S, Mentasti M, Lorini R Minicucci L (2005) Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. Int J Antimicrob Agents 25:193 197.
27. McAuley DF Elborn JS (2000) Cystic fibrosis: basic science. Pediatr Respir Rev 1:93 100.
28. Medeiros AA, O'Brien TF, Wacker WEC Yulug NF (1971) Effect of salt concentration on the apparent in vitro susceptibility of Pseudomonas and other gram-negative bacilli to gentamicin. J Infect Dis 124:S59 S64.
29. Middleton PG, Kidd TJ Williams B (2005) Combined aerosol therapy to treat Burkholderia cepacia complex. Eur Respir J 26:1 4.
30. Poole K (2005) Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:479 487.
31. Ramagopal M Lands LC (2000) Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis. Pediatr Pulmonol 29:366 370.
32. Schweizer HP (2003) Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet Mol Res 2:48 62.
33. Thompson TB, Crider BP Eagon RG (1985) The kinetics of dihydrostreptomycin uptake in Pseudomonas putida membrane vesicles: absence of inhibition by cations. J Antimicrob Chemother 16:157 163.
34. Tummler B Kiewitz C (1999) Cystic fibrosis: an inherited susceptibility to bacterial respiratory infections. Mol Med Today 5:351 358.
35. Vaisman N, Koren G, Goldstein D, Canny GJ, Tan YK, Soldin S Pencharz P (1987) Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults. J Pediatr 111:914 917.
36. Veloira WG, Domenico P, LiPuma JJ, Davis JM, Gurzenda E Kazzaz JA (2003) In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex. J Antimicrob Chemother 52:915 919.
37. Zemelis VM Jackson GG (1973) Activity of aminoglycoside antibiotics against Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism. J Infect Dis 127:663 669.